Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) flow diagram for systematic review of the fracture risks associated with breast cancer treatments.
aNo tamoxifen;
bNo AIs.
AIs, aromatase inhibitors; BMD, bone mineral density; RCT, randomized controlled trial; Tam, tamoxifen.